These large-scale screens can be used to identify vulnerabilities that are selectively essential for certain mutational subtypes (such as BRAF or KRAS mutated cancers) (Jung et al, 2021), or to nominate candidate targets selectively required for cancer types of interest (Behan et al, 2019). This evidence concerns the gene BRAF and cancer.